Skip to content

    R Systems Intl.

    RSYSTEMSGood
    Information Technology·14 Aug 2025
    Management Summary

    R Systems International Limited reported a strong Q2 FY25, demonstrating consistent growth in revenue and profitability. The company saw a 4.4% sequential growth in INR revenue and a significant 53.4% YoY increase in adjusted net profit. Strategic investments in AI and cloud capabilities, coupled with large deal wins, are driving this momentum, despite a temporary increase in DSO due to an ERP system rollout. The company is also preparing for future inorganic growth with significant capital approvals.

    Highlights

    8

    • Revenue of INR 462 crores (USD 54 million), up 4.4% QoQ (INR) and 5.6% QoQ (USD).

    • Adjusted EBITDA at INR 79.7 crores (USD 9.3 million), an 11.7% YoY increase.

    • Adjusted EBITDA margin improved to 17.3% in Q2 FY25 from 16.5% in Q2 FY24.

    • Adjusted Net Profit stood at INR 46.4 crores (USD 5.4 million), a 53.4% YoY increase.

    • DSO increased to 68 days from 61 days, attributed to a one-off ERP rollout delay.

    • Secured 6 new large deals, with average deal size inching closer to $1 million.

    • Added over 190 associates during the quarter, supporting new wins and sales funnel.

    • Board approved INR 2,000 crores loan and INR 275 crores NCD for inorganic growth preparedness.

    Key financials

    Single quarter

    11 metrics
    1. 01Revenue₹462 Cr+6.9%YoY
    2. 02Revenue (USD)54 Mn+4.2%YoY
    3. 03Adjusted EBITDA₹79.7 Cr+11.7%YoY
    4. 04Adjusted EBITDA Margin17.3%+0.8%YoY
    5. 05Adjusted Net Profit₹46.4 Cr+53.4%YoY

    Guidance & targets

    8
    CategoryTargetPriority
    Profitability
    Adjusted EBITDA Margin
    high 16s
    		High
    Capital Allocation
    Acquisition Funding (Loan)
    INR 2,000 crores
    		High
    Capital Allocation
    Acquisition Funding (NCD)
    INR 275 crores
    		High
    Operating Efficiency
    DSO Normalization
    normalize in a quarter or so
    		Medium
    Pipeline Health
    Overall Pipeline Size
    1.25 to 1.4 times bigger
    		High
    Pipeline Health
    Deals in $1M+ ACV category
    more than doubled
    		High
    Headcount Cost
    RSU Expense
    INR 5.5-6 crores
    		Medium
    Revenue Growth
    Year-end Top Line (USD)
    $220 million $230 million
    		Low

    Risks & concerns

    6
    RiskSeverity

    Cautious discretionary spending by clients

    Management notes continued cautious discretionary spending in the market, though data/SaaS platform companies are spending more aggressively. — Management acknowledged

    medium

    Increase in DSO (Days Sales Outstanding)

    DSO increased to 68 days from 61 days due to a one-off billing delay from a global ERP rollout, but is expected to normalize in a quarter or so. — Management acknowledged

    medium

    Seasonal challenges/furloughs in Q4

    Q4 typically faces headwinds from Diwali, Christmas, and New Year holidays, but management hopes strong volume momentum will mitigate the impact. — Management acknowledged

    low

    Escalating AI operational costs

    Increased adoption of AI leads to escalating operational costs, which the company is addressing through a partnership with Mavvrik for AI cost governance. — Management acknowledged

    low

    Areas of Evasion(2)

    • Specific reasons for top 10 client revenue trends beyond 'no client-specific issue'
    • Firm commitment on year-end top line guidance

    Q&A highlights

    3

    “Large deals, as we had spoken last time as well, these are typically multimillion dollar deals spread over a couple of years. So the few large deals that we won, typically, we've seen the 2- or 3-year deal engagements come through. So we are looking at clients who will typically make into between USD 2 million to USD 5 million clients a year kind of a thing.”

    Provides insight into the scale and duration of new client engagements, indicating a shift towards larger, more strategic deals with potential for significant annual revenue.

    asked by Vinay Menon

    3 min read6 chapters

    Detailed Narrative

    01

    Strong Q2 FY25 Financial Performance

    R Systems International reported robust financial results for Q2 FY25, with revenue reaching INR 462 crores (USD 54 million), marking a 4.4% sequential growth in INR terms and 5.6% in USD terms. Adjusted EBITDA stood at INR 79.7 crores (USD 9.3 million), an 11.7% increase year-over-year, with the adjusted EBITDA margin improving to 17.3% from 16.5% in Q2 FY24. Adjusted net profit surged by 53.4% YoY to INR 46.4 crores (USD 5.4 million), translating to an adjusted basic EPS of INR 3.9.

    02

    Operational Metrics and Geographic/Client Mix

    The company maintained a high utilization rate of 82.6%, though slightly down by 120 basis points from its peak. North America continues to be the largest geography, contributing approximately 75% of revenue, with Europe and Southeast Asia making up 8.8% and 12.9% respectively. Client concentration remains stable, with the top 10 clients accounting for 24.6% of revenue. DSO increased to 68 days from 61 days, primarily due to a one-off📎 billing delay caused by a global ERP solution rollout, which is expected to normalize in a quarter or so.

    03

    Strategic Focus on AI, Cloud, and Partnerships

    R Systems is actively enhancing its channel partnerships with major cloud providers like AWS, Azure, and Databricks, and has secured research funding eligibility from Microsoft. A new partnership with Mavvrik addresses AI cost governance, a growing concern with increased AI adoption. The company has significantly increased its focus on Agentic AI offerings, deploying multiple GenAI tools across projects and seeing client endorsements for efficiency gains. Mexico operations are scaling up, now serving five active clients.

    04

    Inorganic Growth Strategy and Capital Preparedness

    The Board has approved an INR 2,000 crores loan and an INR 275 crores NCD as enabling provisions for potential acquisitions, signaling a strong intent for inorganic growth. The primary acquisition targets are in product engineering, digital transformation, cloud data, and AI capabilities, with a focus on North American businesses with India delivery, and potentially delivery locations in Eastern Europe or LatAm. The average working capital cost of capital is 8-8.5%, and NCD rates will be negotiated.

    05

    Growth Outlook and Pipeline Health

    Management expressed confidence in continuing growth momentum into Q3 FY25, driven by solid deal wins and a robust pipeline. The overall pipeline has improved to 1.25 to 1.4 times its previous size, and the number of deals in the $1 million-plus ACV category has more than doubled. While Q4 is expected to face seasonal challenges from furloughs, the company hopes that strong volume momentum will mitigate the impact. The company is consciously focusing on winning multi-year annuity-based revenues.

    06

    Margin Management and Investments

    The company is committed to maintaining adjusted EBITDA margins in the high 16s, with any performance above 17% providing a cushion for strategic investments. Gross margin for Q2 FY25 was 36%, slightly down from 36.7% last quarter, partly due to adding over 190 associates and investments in data and AI. RSU costs for the quarter were INR 4.9 crores, expected to average INR 5.5-6 crores in subsequent quarters. A non-recurring📎 income of INR 40.9 crores from the sale of land and building contributed to a lower effective tax rate of 24% for the quarter.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.